A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC-Reference-Cited by-全球学者库

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

Published:2021-11-30 Issue:1 Volume:14 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Lu Yue¹,Fan Zhenzhen²,Zhu Su‐Jie³⁴⁵,Huang Xiaoxing¹,Zhuang Zhongji¹,Li Yunzhan¹,Deng Zhou¹,Gao Lei²,Hong Xuehui⁶,Zhang Ting¹,Li Li¹,Sun Xihuan¹,Huang Wei¹^ORCID,Zhang Jingfang¹,Liu Yan¹,Zhang Baoding¹,Jiang Jie¹,Gui Fu¹^ORCID,Wang Zheng¹^ORCID,Li Qiyuan⁷,Song Siyang¹,Huang Xin⁸,Wu Qiao¹,Chen Lanfen¹,Zhou Dawang¹,Zhang Jianming⁹^ORCID,Yun Cai‐Hong³⁴^ORCID,Chen Liang²^ORCID,Deng Xianming¹^ORCID

Affiliation:

1. State Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Xiamen China

2. Institute of Life and Health Engineering Jinan University Guangzhou China

3. Department of Biochemistry and Biophysics Institute of Systems Biomedicine Peking University Health Science Center Beijing China

4. Beijing Key Laboratory of Tumor Systems Biology School of Basic Medical Sciences Peking University Health Science Center Beijing China

5. Institute for Translational Medicine College of Medicine Qingdao University Qingdao China

6. Department of Gastrointestinal Surgery Affiliated Zhongshan Hospital of Xiamen University Xiamen China

7. National Institute for Data Science in Health and Medicine School of Medicine Xiamen University Xiamen China

8. Division of Drug Discovery Hongyun Biotech Co., Ltd. Nanjing China

9. National Research Center for Translational Medicine Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China

Funder

National Key Research and Development Program of China

Fundamental Research Funds for the Central Universities

Xiamen Municipal Bureau of Science and Technology

National Natural Science Foundation of China

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.202114296

Reference52 articles.

1. PHENIX: a comprehensive Python-based system for macromolecular structure solution

2. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

3. ALK inhibitors in non‐small cell lung cancer: crizotinib and beyond;Awad MM;Clin Adv Hematol Oncol,2014

4. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs

5. The SWISS-MODEL Repository—new features and functionality

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27

2. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms;Frontiers in Pharmacology;2023-10-25

3. Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine;Medical Oncology;2023-10-07

4. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells;Chemico-Biological Interactions;2023-07

5. Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-05